Adding CD28 costimulation to cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cells targeting CD70+ cancers significantly enhanced antitumor efficacy and long-term cytotoxicity of the CAR NK cells, according ...
Jun 20, 2024
0
1
CAR-T cells are highly effective in treating selected blood cancers. However, challenges remain with this new therapy, which was first approved in 2017 in the U.S. and a year later in Europe for treating acute lymphoblastic ...
Aug 2, 2024
0
1
A secondary analysis of the historic RTOG 9202 prostate cancer trial examined results of men with intermediate-risk prostate cancer who had received long-term hormonal therapy after radiation therapy, and concluded that there ...
Sep 23, 2013
0
0
Hepatocellular carcinoma (HCC), a prevalent form of cancer, profoundly influences the progression and prognosis of the disease through immune response mechanisms. The tumor microenvironment plays a pivotal role in fostering ...
May 22, 2024
0
0
When the immune system mobilizes its troops, antigen-presenting cells play an important role. They emerge from white blood cells (monocytes) that circulate in the blood. An international research team under the leadership ...
Dec 20, 2017
0
0
In a study published in the journal National Science Review, a research team aimed to enhance treatment efficacy of CAR-T cell therapy for solid tumors. The research was led by Dr. Zhen Gu and Dr. Hongjun Li from the College ...
Mar 22, 2024
0
0
In the exploration of cancer treatment modalities, an article published in Biomolecules and Biomedicine titled "CAR-macrophage versus CAR-T for solid tumors: The race between a rising star and a superstar," offers an examination ...
Jan 17, 2024
0
1
